Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Next Previous
Search
Trial Profile

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Acronyms REACH2
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 01 Jul 2024 Results assessing efficacy and safety findings of ruxolitinib versus best available therapy (BAT) from a subgroup analysis published in the International Journal of Hematology
    • 21 Mar 2023 Results of post hoc analysis from REACH2 and REACH3 trials assessing the ruxolitinib efficacy in patients with dermatologic manifestations of graft-versus-host disease, presented at the American Academy of Dermatology annual Meeting 2023.
    • 06 Mar 2023 According to Incyte Media Release, A Post Hoc Analysis of the Phase 3 REACH2 and REACH3 Studies will be presented at the upcoming 2023 American Academy of Dermatology (AAD) Annual Meeting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top